Shares of Gilead Sciences Inc. rose 3.07% to $106.34 Monday, on what proved to be an all-around great trading session for the ...

The biotech Gilead Sciences has been the best-performing healthcare stock in the S&P 500 by far over the past 12 months. Its ...

ViiV leads the 2024/25 pharma company reputation rankings, with the PatientView report also finding ways in which the ...

The Handmaid's Tale' is inching towards its conclusion and June, Luke and Moira are putting their plans to take down Gilead ...

Gilead Sciences offers steady dividend growth with a 2.99% yield. Read why the analyst nonetheless has a neutral rating on ...

The company's first-quarter revenue slipped 0.3% year-over-year to $6.67 billion, while analysts surveyed by Visible Alpha ...

Gilead Sciences' Q1 2025 earnings reveal challenges in oncology and Veklury sales, while HIV therapies remain strong. See why ...

In The Handmaid's Tale season 6, June Osborne and Nick Blaine's tumultuous relationship is once again front and center.

Gilead Sciences on Thursday reported a first-quarter profit, but revenue was flat, as higher sales of drugs for HIV and liver ...